Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic myeloproliferative neoplasms

Response to: Ruxolitinib withdrawal due to the COVID-19

To the Editor:

The comment raised by Dr. Lucijanic and Kusec that the effect on high mortality in patients with MPN and COVID-19 could not so much be due to the suspension of ruxolitinib but to the greater severity of the disease was obviously considered in our analysis [1], both in the multivariate model and in the propensity score (PS) matching.

First of all, we clarify that the logistic model presented was not only performed on 45 patients exposed to ruxolitinib. The model considered the entire cohort and adjusted the exposition to ruxolitinib for its discontinuation through the technique of mediation analysis [2].

We were aware that, given the low number of events, the logistic model did not allow to correct for many confounders and for this reason we also performed a sensitivity analysis applying the PS matching. As Supplementary Table 1S shows, there were no significant differences between those who discontinued and those who did not discontinue after PS matching.

This finding should alert the haematologist who cares for patients with MPN treated with ruxolitinib, who contract COVID-19.

References

  1. 1.

    Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021. https://doi.org/10.1038/s41375-020-01107-y.

  2. 2.

    Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol. 2013;42:1511–9.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tiziano Barbui.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Barbui, T., Carobbio, A. Response to: Ruxolitinib withdrawal due to the COVID-19. Leukemia 35, 1219 (2021). https://doi.org/10.1038/s41375-021-01187-4

Download citation

Search

Quick links